MeiraGTx Holdings PLC
MGTX7.845USD
+0.195+2.55%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
623.04MCap. mercado
PérdidaP/E TTM
Más Datos de MeiraGTx Holdings PLC Compañía
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Información de la empresa
Símbolo de cotizaciónMGTX
Nombre de la empresaMeiraGTx Holdings PLC
Fecha de salida a bolsaJun 08, 2018
Director ejecutivoDr. Alexandria Forbes, Ph.D.
Número de empleados381
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 08
Dirección450 East 29Th Street
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10016
Teléfono16468607985
Sitio Webhttps://meiragtx.com/
Símbolo de cotizaciónMGTX
Fecha de salida a bolsaJun 08, 2018
Director ejecutivoDr. Alexandria Forbes, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 4 de jun
Actualizado: mié., 4 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
21.86%
Corporation
20.11%
Private Equity
15.65%
Venture Capital
8.26%
Investment Advisor
7.44%
Investment Advisor/Hedge Fund
5.60%
Individual Investor
4.27%
Research Firm
0.89%
Pension Fund
0.08%
Other
15.83%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
230
67.81M
84.38%
+4.14M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
12.58M
15.65%
--
--
Mar 31, 2025
Sanofi SA
12.20M
15.18%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
5.63M
7.01%
+600.00K
+11.92%
Mar 31, 2025
Prosight Capital
3.69M
4.59%
-699.29K
-15.93%
Mar 31, 2025
Adena Estate Inc.
3.27M
4.06%
+3.27M
--
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
2.73M
3.39%
+87.69K
+3.32%
Mar 31, 2025
683 Capital Management LLC
2.58M
3.2%
+160.00K
+6.63%
Mar 31, 2025
Rubric Capital Management LP
1.78M
2.21%
+1.78M
--
Mar 31, 2025
Forbes (Alexandria)
1.41M
1.75%
-47.50K
-3.26%
Apr 08, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
Goldman Sachs Innovate Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Ver más
iShares Micro-Cap ETF
Proporción0.06%
ProShares Ultra Nasdaq Biotechnology
Proporción0.06%
Invesco Nasdaq Biotechnology ETF
Proporción0.06%
Goldman Sachs Innovate Equity ETF
Proporción0.04%
iShares Biotechnology ETF
Proporción0.04%
SPDR S&P International Small Cap ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
